奥曲肽治疗晚期原发性肝癌的临床观察

The clinical study of octreotide for adcvanced primary hepatic cancer

目的:观察生长抑素类似物奥曲肽治疗晚期原发性肝癌的临床疗效。方法:将44例晚期原发性肝癌患者分为治疗组与对照组,治疗组20例,使用奥曲肽0.1mg,皮下注射,每12小时1次,至病情有进展时停药;对照组24例,仅接受支持治疗。每1个月进行1次疗效评价,比较两组疗效。结果:治疗组中无CR,3例PR,2例NC,15例PD。总有效率为15%。对照组中无CR、PR,4例NC,20例PD。总有效率为0。两组有显著性差异(P<0.05)。治疗组中位生存期为7.5个月,对照组中位生存期为2.5个月,有显著性差异(P<0.05)。治疗组中位TTP为5个月,对照组为2.5个月,有显著性差异(P<0.05)。治疗组生活质量较对照组有明显提高(P<0.05),上消化道出血的发生率治疗组较对照组明显减少。结论:奥曲肽可延长晚期原发性肝癌患者的生存期,提高生活质量。

Objective：To evaluate the effect of octreotide for advanced primary hepatic cancer. Methods：Total of 44 patients were enrolled, and divided into the treatment group and the control group,20 patients in the treatment group were given octreotide at a dose of 0. 1mg q12h till the disease progressed,24 patients in the control group were given the best supportive care only. The effect was evaluated and compared between the two groups once a month. Results：The overall response rate in the treatment group was 15 % including 0 CR,3 PR,2 NC, 15 PD,while in the control group was 0% ,including 0 CR,0 PR,4 NC,20 PD,there was significant difference between the two groups（P 〈 0.05）. The median survial time in the treatment group and the control group was 7.5 months ,2.5 months respectively with a significant stastical difference（ P 〈 0.05 ）. The time to tumor progression（TTP） in the treatment group and the control group was 5 months ,2.5 months respectively with a significant stastical difference（ P 〈 0.05 ）. The patients in the treatment group has a significantly improved quality of life and a lesser ocurrence rate of upper gastrointestinal hemorrahage compared with the control group. Conclusion：The use of octreotide in primary hepatic cancer can prolong the survival time and improve the quality of life of patients effectively.